Canopy Growth (CGC) Shares Outstanding (2017 - 2026)
Canopy Growth (CGC) posted Shares Outstanding (Entity) of $298.0 million for Q1 2026, down 19.07% sequentially from $368.3 million in Q4 2025, and up 177.11% YoY from $107.6 million in Q1 2025.
Canopy Growth (CGC) Shares Outstanding (2017 - 2026) Analysis & Trends
Canopy Growth has reported Shares Outstanding (Entity) for 10 years, with the latest figure at $298.0 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 177.11% year-over-year to $298.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $298.0 million (up 177.11% YoY) and the FY2026 annual result came in at $298.0 million, up 177.11% from the prior year.
- Shares Outstanding (Entity) fell to $298.0 million in Q1 2026 per CGC's latest filing, from $368.3 million in the prior quarter.
- Over five years, Shares Outstanding (Entity) peaked at $368.3 million in Q4 2025 and troughed at $39.4 million in Q1 2022.
- A 5-year average of $123.0 million and a median of $82.9 million in 2023 frame the typical range for Shares Outstanding (Entity).
- The sharpest annual moves came in 2022 and 2025: Shares Outstanding (Entity) increased 3.02% in 2022, then soared 191.94% in 2025.
- Over 5 years, Shares Outstanding (Entity) stood at $49.5 million in 2022, then surged by 67.58% to $82.9 million in 2023, then soared by 55.73% to $129.2 million in 2024, then jumped by 185.15% to $368.3 million in 2025, then dropped by 19.07% to $298.0 million in 2026.
- According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $298.0 million, $368.3 million, and $274.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | 4.44 Bn |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | 1.17 Bn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | 417.60 Mn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | 1.58 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | 42.60 Mn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | 1.16 Bn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 101.00 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | 499.50 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | 832.44 Mn |
| 10 | Canopy Growth | 431.13 Mn | 184.12 Mn | 16.08 Mn | 422.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 422.26 Mn |
| Mar 31, 2026 | 298.04 Mn |
| Dec 31, 2025 | 345.53 Mn |
| Sep 30, 2025 | 274.03 Mn |
| Jun 30, 2025 | 188.32 Mn |
| Mar 31, 2025 | 107.55 Mn |
| Dec 31, 2024 | 110.31 Mn |
| Sep 30, 2024 | 86.83 Mn |
| Jun 30, 2024 | 79.24 Mn |
| Mar 31, 2024 | 74.79 Mn |
| Dec 31, 2023 | 82.92 Mn |
| Sep 30, 2023 | 71.63 Mn |
| Jun 30, 2023 | 55.05 Mn |
| Mar 31, 2023 | 46.37 Mn |
| Dec 31, 2022 | 48.61 Mn |
| Sep 30, 2022 | 47.16 Mn |
| Jun 30, 2022 | 39.85 Mn |
| Mar 31, 2022 | 39.13 Mn |
| Dec 31, 2021 | 39.38 Mn |
| Sep 30, 2021 | 39.33 Mn |